{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:17:43Z","timestamp":1788635863237,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.numecd.2024.103845","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T11:15:48Z","timestamp":1735384548000},"page":"103845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["LP(a): The new marker of high cardiovascular risk"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-9209","authenticated-orcid":false,"given":"Maurizio","family":"Averna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo B.","family":"Cefal\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2024.103845_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.numecd.2024.103845_bib2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103845_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.metabol.2004.10.001","article-title":"The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings","volume":"54","author":"Jennera","year":"2005","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.numecd.2024.103845_bib4","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.103845_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"Chemello","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.103845_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2024.103845_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/clinchem\/45.7.1039","article-title":"Lipoprotein(a)-Cholesterol and coronary heart disease in the Framingham","volume":"45","author":"Seman","year":"1999","journal-title":"Heart Study Clinical Chemistry"},{"key":"10.1016\/j.numecd.2024.103845_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.103845_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.103845_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103845_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: prospects, potentials, and limitations","volume":"33","author":"Smith","year":"2004","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.numecd.2024.103845_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/aje\/kwj062","article-title":"Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials","volume":"163","author":"Nitsch","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.numecd.2024.103845_bib14","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib15","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.103845_bib16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the Copenhagen General Population Study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.116.026103","article-title":"A replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-Analysis of Published and Novel Data","volume":"135","author":"Cairns","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103845_bib18","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib19","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.jacc.2012.02.093","article-title":"Calcific aortic stenosis: a disease of the valve and the myocardium","volume":"60","author":"Dweck","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib20","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib21","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common LPA null allele is associated with lower lipoprotein(a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian Randomization Study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2024.103845_bib23","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2024.103845_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1194\/jlr.C085639","article-title":"In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes","volume":"59","author":"Tsimikas","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.103845_bib25","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103845_bib26","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.numecd.2024.103845_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0129","article-title":"Association of long-term exposure to elevated lipoprotein(a) levels with parental life span, chronic disease-free survival, and mortality risk: a Mendelian Randomization Analysis","volume":"3","author":"Arsenault","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.numecd.2024.103845_bib29","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.numecd.2023.07.019","article-title":"Consensus document on lipoprotein (a) from the Italian society for the study of atherosclerosis (SISA)","volume":"33","author":"Chiesa","year":"2023","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2024.103845_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular diseaseLipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.numecd.2024.103845_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein (a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.103845_bib31","first-page":"191","volume":"vol. 38","author":"Rosenson","year":"2024"},{"key":"10.1016\/j.numecd.2024.103845_bib32","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00015a028","article-title":"Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation","volume":"34","author":"Sangrar","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.numecd.2024.103845_bib33","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.numecd.2024.103845_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/01.ATV.9.5.579","article-title":"Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients","volume":"9","author":"Rath","year":"1989","journal-title":"Arteriosclerosis"},{"issue":"3","key":"10.1016\/j.numecd.2024.103845_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2023.09.836","article-title":"Per-particle cardiovascular risk of lipoprotein(a) vs non-lp(a) apolipoprotein B-containing lipoproteins","volume":"83","author":"Marston","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib36","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/ATVBAHA.123.319937","article-title":"Jeffrey kroon diacylglycerols and lysophosphatidic Acid,Enriched on lipoprotein(a), contribute to monocyte inflammation","volume":"44","author":"Dzobo","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","article-title":"Lipoprotein(a): from causality to treatment, florian kronenberg","volume":"26","year":"2024","journal-title":"Curr Atherosclerosis Rep"},{"issue":"9","key":"10.1016\/j.numecd.2024.103845_bib38","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression A systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"17","key":"10.1016\/j.numecd.2024.103845_bib39","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Marc R dweck lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2024.103845_bib40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.123.066822","article-title":"Major facilitator superfamily domain containing 5 inhibition reduces lipoprotein(a) uptake and calcification in valvular heart disease","volume":"149","author":"Rogers","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103845_bib41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12916-024-03342-x","article-title":"Autotaxin inhibition attenuates the aortic valve calcifcation by suppressing infammation-driven fbro-calcifc remodeling of valvular interstitial cells, l","volume":"22","author":"Yoon","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.numecd.2024.103845_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.ATV.18.3.441","article-title":"Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1","volume":"18","author":"Ginsberg","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib43","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/ajcn\/86.5.1611","article-title":"Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states","volume":"86","author":"Berglund","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.numecd.2024.103845_bib44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.103845_bib45","first-page":"16","article-title":"Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein(a)","volume":"1","author":"Nugent","year":"2020","journal-title":"J Clin Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib46","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.103845_bib47","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1016\/j.atherosclerosis.2021.06.067","article-title":"The German lipoprotein apheresis Registry (GLAR) - more than 7 years on [abstract]","volume":"331","author":"Schettler","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2024.103845_bib48","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a) associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib49","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.numecd.2024.103845_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"key":"10.1016\/j.numecd.2024.103845_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) coronary angiography","volume":"14","author":"Safarova","year":"2013","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.numecd.2024.103845_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patientdata meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.numecd.2024.103845_bib53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib54","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103845_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2024.103845_bib56","first-page":"853","article-title":"Role of bempedoic acid in clinical practice, Cardiovasc","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Drugs Ther"},{"key":"10.1016\/j.numecd.2024.103845_bib57","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2024.103845_bib58","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2024.103845_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib60","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Aim-High Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib62","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103845_bib63","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib64","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein (a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.numecd.2024.103845_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011903","article-title":"Lipoprotein (a) removal still a mystery","volume":"8","author":"Nestel","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2024.103845_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2024.103845_bib67","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib68","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib69","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103845_bib70","unstructured":"www.clinicaltrials.gov accessed 15 October 2024.NCT03705234. \"A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People with Cardiovascular Disease (ORION-4)."},{"key":"10.1016\/j.numecd.2024.103845_bib71","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacl.2017.10.001","article-title":"Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk","volume":"12","author":"Arsenault","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.numecd.2024.103845_bib72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2024.103845_bib73","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2024.103845_bib74","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2024.103845_bib75","first-page":"e563","article-title":"Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins","volume":"18","author":"Hsieh","year":"2024","journal-title":"Journal of Clinical Lipidology"},{"issue":"12","key":"10.1016\/j.numecd.2024.103845_bib76","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/eurheartj\/ehs084","article-title":"Antisense oligonucleotides for the treatment of dyslipidaemia","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"issue":"10002","key":"10.1016\/j.numecd.2024.103845_bib77","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"10057","key":"10.1016\/j.numecd.2024.103845_bib78","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2024.103845_bib79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib80","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.numecd.2024.103845_bib81","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.numecd.2024.103845_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events and lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.numecd.2024.103845_bib83","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"OCEAN(a)-DOSE trial investigators. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103845_bib84","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","article-title":"Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease","volume":"349","author":"Rider","year":"2022","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.numecd.2024.103845_bib85","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.numecd.2024.103845_bib86","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"14","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.103845_bib87","article-title":"Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.numecd.2024.103845_bib88","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.numecd.2024.103845_bib89","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.103845_bib90","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","author":"Nicholls","year":"2024","journal-title":"JAMA"},{"issue":"Suppl_1","key":"10.1016\/j.numecd.2024.103845_bib91","article-title":"CTX320: an investigational in vivo CRISPR-based therapy efficiently and durably reduces lipoprotein (a) levels in non-human primates after a single dose","volume":"148","author":"Morrow","year":"2023","journal-title":"Circulation"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324004794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324004794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T16:17:30Z","timestamp":1741796250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475324004794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0939475324004794"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.103845","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LP(a): The new marker of high cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.103845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"103845"}}